RxDoctor Payments Data

Jesse Eisenman, MD

Gastroenterology · Lake Worth, FLNPI 1770581720

Payments from drug & device makers

$8,966in general payments, 2019–2025

Across 449 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gilead$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$944
  • Johnson & Johnson$831
  • Phathom Pharmaceuticals, Inc.$410
  • Bristol Myers Squibb$407
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$8,82398%
  • Education$1432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,966 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$51,997
Medicare patients
228
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib11$71,708
LinzessLinaclotide15$15,169
ClenpiqSod Picosulf/Mag Ox/Citric Ac73$12,402
VoqueznaVonoprazan Fumarate13$9,767
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates60$4,173
Pantoprazole Sodium375$4,046
SutabSod Sulf/Pot Chloride/Mag Sulf18$2,959
Lubiprostone19$1,178
Dicyclomine Hcl47$783
Famotidine73$723
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl49$608
CholestyramineCholestyramine (With Sugar)13$582
Omeprazole42$306
Ondansetron Hcl15$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$2,225$86,87726 claims
Ferring Pharmaceuticals Inc.Clenpiq$107$12,40273 claims
Phathom Pharmaceuticals, Inc.Voquezna$410$9,76713 claims
Braintree Laboratories, Inc.Sutab$138$2,95918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Lake Worth

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →